Related Experiment Video
Updated: Feb 26, 2026
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines
1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY 10029, USA.
Abstract:
Development of therapeutic cancer vaccines has been hindered by the many pro-tumorigenic mechanisms at play in cancer patients that serve to suppress both antigen presenting cells and T cells. In face of these obstacles, cancer vaccines are most likely to promote anti-tumorigenic immune responses only when formulated with strong adjuvants, and in combination with new immune interventions designed to reverse immune suppression and exhaustion of T cells in the tumor microenvironment. Dendritic cells (DCs) are often termed 'nature's adjuvant' due to their exceptional capacity for initiating both innate and adaptive immune responses. Hence, the past decade has witnessed a flurry of activity in testing DC based immunotherapies for cancer intervention. In this review we will discuss advances in conventional adjuvants and provide insight into new adjuvants as they pertain to DC cancer therapy.
Insights
Therapeutic cancer vaccines face challenges from tumor-induced immune suppression. Combining strong adjuvants with dendritic cell (DC) therapies can overcome these hurdles for effective anti-tumor immune responses.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Cancer vaccines are hindered by pro-tumorigenic mechanisms suppressing immune cells.
- Effective cancer vaccines require strong adjuvants and immune interventions to reverse T cell exhaustion.
- Dendritic cells (DCs) are potent immune stimulators, acting as natural adjuvants.
Purpose of the Study:
- To review advances in conventional and novel adjuvants for dendritic cell (DC) based cancer therapy.
- To provide insights into overcoming immune suppression in the tumor microenvironment for cancer vaccine development.
Main Methods:
- Review of current literature on cancer vaccine adjuvants.
- Analysis of the role of dendritic cells (DCs) in initiating immune responses.
- Discussion of strategies to reverse immune suppression and T cell exhaustion.
Main Results:
- Adjuvants are crucial for promoting anti-tumorigenic immune responses in cancer vaccines.
- Dendritic cell (DC) based immunotherapies show significant promise in cancer intervention.
- New immune interventions are needed to synergize with adjuvants and DCs.
Conclusions:
- Overcoming immune suppression is key for successful therapeutic cancer vaccines.
- Dendritic cell (DC) therapies, when combined with advanced adjuvants, offer a promising strategy.
- Further research into novel adjuvants and immune interventions is essential for effective cancer immunotherapy.
More Related Videos
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
01:51Vaccinations